Abstracts Archive - Page 2106 of 2607 - ACR Meeting Abstracts

Abstract Number: 1918 • 2014 ACR/ARHP Annual Meeting
IL23 Overexpression Demonstrates Gut-Joint Inflammation Link and Increased Expression of Spondyloarthopathy Associated Genes In Vivo
Donald Souza II, Immunology & Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: It has been well established that a close relationship exists between gut inflammation and spondyloarthropathies. Polymorphisms in the receptor for IL23 are associated not…
Abstract Number: 1917 • 2014 ACR/ARHP Annual Meeting
IL-23 Expression and Activation of Autophagy in Synovium and PBMCs of HLA-B27 Positive Patients with Ankylosing Spondylitis
Barbara Neerinckx, Shea Carter and Rik J. Lories, Laboratory of Tissue Homeostasis and Disease - SBE Research Center, KU Leuven, Leuven, Belgium
Background/Purpose: IL-23 may play a key role in the pathogenesis of ankylosing spondylitis (AS). Some studies describe indeed increased serum levels of IL-23 in AS…
Abstract Number: 1916 • 2014 ACR/ARHP Annual Meeting
Stromal Overexpression of Transmembrane TNF Induces Spa-like Arthritis and Spondylitis in Mice
Leonie M. van Duivenvoorde^1,2, Melissa N. van Tok³ and Dominique L. Baeten^1,4, ¹Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Experimental Immunology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The immunopathology of spondyloarthritis (SpA) is determined by inflammation and structural damage, in particular osteoproliferation, of axial and peripheral joints. The failure of TNF…
Abstract Number: 1915 • 2014 ACR/ARHP Annual Meeting
IL-17 Gene Transfer induces Myeloid Precursor Cells That Initiate Epidermal Hyperplasia Independently of IL-23R⁺/CD4⁺ and γδ T Cells
Erika Suzuki¹, Ritu Sarin², Emanual Maverakis¹ and Iannis E. Adamopoulos², ¹University of California at Davis, Sacramento, CA, ²Internal Medicine, University of California at Davis, Sacramento, CA
Background/Purpose: IL-17 is elevated in both the lesional skin and arthritic joints of psoriatic arthritis (PsA) patients. Although the IL-23/IL-17 axis has been linked with…
Abstract Number: 1914 • 2014 ACR/ARHP Annual Meeting
IL-17A Deficiency Promotes Periosteal Bone Formation in a Model of Inflammatory Arthritis
Anita T. Shaw¹, Yukiko Maeda¹, Catherine Manning¹ and Ellen M. Gravallese^1,2, ¹Department of Medicine, Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA, ²Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Enthesial and periosteal bone formation in spondyloarthropathies (SpAs) are important sequelae of disease that contribute to patient morbidity. Anti-TNF therapies do not significantly alter…
Abstract Number: 1913 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases
Silvia Rollefstad¹, Eirik Ikdahl¹, Jonny Hisdal², Inge C. Olsen³, Ingar Holme⁴, Hilde Berner Hammer⁵, Knut T. Smerud⁶, G Kitas⁷, Terje R. Pedersen⁸, Tore K. Kvien⁹ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, ⁵Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁶Smerud Medical Research International AS, Oslo, Norway, ⁷The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ⁸Faculty of Medicine, University of Oslo, Oslo, Norway, ⁹PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol…
Abstract Number: 1912 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency
Shunsuke Mori, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan
Background/Purpose: Renal involvement is relatively common in rheumatoid arthritis (RA) patients. Recent randomized controlled trials of anti-tumor necrosis factor-α (anti-TNFα) showed that the concomitant administration…
Abstract Number: 1911 • 2014 ACR/ARHP Annual Meeting
Disease Modifying Anti-Rheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients with Early Rheumatoid Arthritis: A Retrospective Cohort Study
Rishi Desai¹, Wesley Eddings², Katherine Liao³, DH Solomon⁴ and Seoyoung C. Kim⁵, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁵Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) increases patients' risk of developing cardiovascular diseases (CVD). Hyperlipidemia is an important CVD risk factor in the general population. The objective…
Abstract Number: 1910 • 2014 ACR/ARHP Annual Meeting
Risk of Hypersensitiviy Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics
Huifeng Yun¹, Fenglong Xie², Lang Chen³, James Lewis⁴ and Jeffrey R. Curtis⁵, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Healthcare providers have been alerted to the potential drug hypersensitivity reactions (HSRs, an adverse drug reaction that are uncommon but may be severe and…
Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting
Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Alper van Sijl¹, Mamas Mamas², Mark Lunt^3,4, . BSRBR Control Centre Consortium³, Kath Watson⁵, Deborah P. Symmons^3,6 and Kimme L. Hyrich⁷, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…
Abstract Number: 1927 • 2014 ACR/ARHP Annual Meeting
A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil
Ami A. Shah¹, Elena Schiopu², Soumya Chatterjee³, Mary Ellen Csuka⁴, Tracy Frech⁵, Avram Goldberg⁶, Robert F. Spiera⁷, Stanford L. Peng⁸ and Virginia D. Steen⁹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁵Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Div of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Benaroya Research Institute/Virginia Mason, Seattle, WA, ⁹Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose Ischemic digital ulcers (DU) occur in over 40% of systemic sclerosis (SSc) patients. Treprostinil diolamine, a newer prostacyclin analog that has been developed for…
Abstract Number: 1926 • 2014 ACR/ARHP Annual Meeting
Nailfold Videocapillaroscopy Patterns Associated with Calcinosis and Acro-Osteolysis in Systemic Sclerosis
Jerome Avouac¹, Laetitia Morardet², Maya Sammour³, Andre Kahan², Antoine Feydy³ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France
Background/Purpose: Calcinosis and acro-osteolysis are frequent in systemic sclerosis (SSc). They may be related to digital vasculopathy, which can be assessed by nailfold videocapillaroscopy (NVC).…
Abstract Number: 1925 • 2014 ACR/ARHP Annual Meeting
Determinants of Blood Hydroxychloroquine Concentration Variations in Systemic Lupus Erythematosus Patients
Moez Jallouli¹, Lionel Galicier², Olivier Aumaître³, Camille Francès⁴, Véronique Le-Guern⁵, F. Lioté⁶, Amar Smail⁷, Nicolas Limal⁸, L. Perard⁹, H. Desmurs-Clavel¹⁰, Du Boutin¹¹, B. Asli¹², Jean Emmanuel Kahn¹³, Jacques Pourrat¹⁴, Laurent Sailler¹⁵, F. Ackermann^1,13, T. Papo¹⁶, Karim Sacre¹⁷, O. Fain¹⁸, J. Stirnemann¹⁸, Patrice Cacoub¹⁹, Gaëlle Leroux²⁰, Judith Cohen-Bittan²¹, Js Hulot²², Zahir Amoura²³, Jean-Charles Piette²⁴ and Nathalie Costedoat-Chalumeau²⁵, ¹Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²Internal Medicine, Hopital St Louis, AP-HP, Paris, France, ³Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁴service de dermatologie allergologie, Hôpital Tenon, Paris Cedex 20, France, ⁵service de médecine interne, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶service de rhumatologie, Hôpital Lariboisière, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France, ⁷Internal Medicine Department, CHU Amiens Nord, Amiens, France, ⁸Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ⁹service de médecine interne, Hospices Civils de Lyon, groupement Hospitalier Edouard Herriot, Lyon, France, ¹⁰service de médecine interne, Hospice civils de Lyon, Lyon, France, ¹¹Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ¹²Departement of clinical immunology, Hopital Saint Louis, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, ¹³internal medicine, Hopital Foch, Suresnes, France, ¹⁴nephrolohy, CHU Toulouse, Hopital Rangueil, University of Paul Sabatier, Toulouse, France, ¹⁵Service de Médecine Interne, S, CHU Toulouse, Hopital Purpan, University of Paul Sabatier, Toulouse, France, ¹⁶Internal Medicine, Hopital Bichat Claude Bernard, University of Paris Diderot, Sorbonne Paris cité, Paris, FL, France, ¹⁷Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ¹⁸Internal Medicine, Hopital Jean Verdier, University Paris Nord, Sorbonne Paris Cité, Paris, France, ¹⁹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ²⁰Department of Internal Medicine 1, CHU Pitié-Salpêtrière, Paris, France, ²¹Service de medecine gériatrique, CHU Pitié-Salpêtrière, Paris, France, ²²Pharmacology, CHU Pitié-Salpêtrière, UPMC, University Paris 6, Paris, France, ²³Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²⁴Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ²⁵Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Hydroxychloroquine (HCQ) is now recognized as an important treatment of systemic lupus erythematosus (SLE). Blood HCQ levels ([HCQ]) can be quantified by high performance…
Abstract Number: 1924 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus
Rosalind Ramsey-Goldman¹, Richard Furie², Chaim Putterman³, Anka Askanase⁴, Jill P. Buyon⁵, Kenneth Kalunian⁶, W. Winn Chatham⁷, E Massarotti⁸, Kyriakos A. Kirou⁹, A. Weinstein¹⁰, Puja Chitkara¹¹, Susan Manzi¹², Joe Ahearn¹³, Leilani Wolover¹⁴, John Conklin¹⁵, Tyler O'Malley¹⁴, Claudia Ibarra¹⁵, Derren Barken¹⁶ and Thierry Dervieux¹⁷, ¹FSM-300, Northwestern University, Chicago, IL, ²Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Department of Medicine Rhemuatology, Colombia University, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Washington Hospital Center, Washington, DC, ¹¹Internal Medicine, Sharp Memorial Hospital, San Diego, CA, ¹²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹³Internal Medicine, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁴Research and Development, Exagen Diagnostics, Inc., Vista, CA, ¹⁵1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ¹⁶Exagen Diagnostics, Inc., Vista, CA, ¹⁷rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell bound complement activation products (CBCAPS) have been established as valuable biomarkers in the diagnosis of Systemic Lupus Erythematosus (SLE). In…
Abstract Number: 1896 • 2014 ACR/ARHP Annual Meeting
Validation of a Novel IFN-Regulated Gene Score As Biomarker in Chronic Atypical Neutrophilic Dermatosis with Lipdoystrophy and Elevated Temperature (CANDLE) Patients on Baricitinib, a Janus Kinase 1 /2 Inhibitor, a Proof of Concept
Hanna Kim¹, Steve Brooks², Yin Liu¹, Adriana Almeida de Jesus³, Gina A. Montealegre Sanchez¹, Dawn C. Chapelle¹, Nicole Plass¹, Yan Huang¹ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD, ³Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose CANDLE syndrome is a novel autoinflammatory disease with strong IFN response signature. We hypothesize that IFN dysregulation may drive clinical manifestations in CANDLE and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].